Citadel Advisors
CGON icon

Citadel Advisors’s CG Oncology CGON Stock Holding History

Citadel Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$703K Sell
9,900
-26,800
-73% -$1.75M ﹤0.01% 9070
2026
Q1 		$2.48M Buy
36,700
+300
+0.8% +$17K ﹤0.01% 5636
2025
Q4 		$1.51M Buy
36,400
+29,800
+452% +$1.23M ﹤0.01% 6495
2025
Q3 		$266K Sell
6,600
-29,700
-82% -$863K ﹤0.01% 10631
2025
Q2 		$944K Buy
36,300
+4,800
+15% +$116K ﹤0.01% 7232
2025
Q1 		$771K Sell
31,500
-3,000
-9% -$84.4K ﹤0.01% 7533
2024
Q4 		$989K Buy
34,500
+14,300
+71% +$489K ﹤0.01% 7045
2024
Q3 		$762K Buy
20,200
+3,900
+24% +$137K ﹤0.01% 7382
2024
Q2 		$515K Buy
16,300
+14,300
+715% +$496K ﹤0.01% 7981
2024
Q1 		$87.8K Buy
+2,000
New +$81.7K ﹤0.01% 11526

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's CGON Position: Q2 2026 in Review

Citadel Advisors sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 172,815 shares — an estimated $11.3M sold.

Citadel Advisors first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $33.5M in Q4 2024. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Citadel Advisors reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 172,815 CG Oncology shares in Q2 2026, an estimated $11.3M.
  • Citadel Advisors first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
  • Citadel Advisors's CG Oncology position peaked at $33.5M in Q4 2024.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.